Trials / Completed
CompletedNCT03237845
Safety and Efficacy in Adult Subjects With Acute Migraines
BHV3000-302 : Phase 3: Double-Blind, Randomized, Placebo-Controlled, Safety and Efficacy Trial of BHV-3000 (Rimegepant) for the Acute Treatment of Migraine
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 1,499 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to compare the efficacy of BHV-3000 (rimegepant) versus placebo in subjects with Acute Migraines
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rimegepant | 75 mg tablet QD |
| DRUG | Placebo | Placebo tablet to match rimegepant dose QD |
Timeline
- Start date
- 2017-07-27
- Primary completion
- 2018-01-25
- Completion
- 2018-01-31
- First posted
- 2017-08-03
- Last updated
- 2023-02-16
- Results posted
- 2020-12-23
Locations
50 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03237845. Inclusion in this directory is not an endorsement.